Reimbursement Limits Threaten Drug Access
Despite provisions in the Affordable Care Act that require qualified health plans to cover 'basic' benefits, access to prescription drugs may be limited by high out-of-pocket costs and tight pharmacy management strategies.
Gravity Shift: What MNCs Can Learn from Generics
MNCs can learn a lot from generic companies in their strategic approaches to emerging markets.
The Brands of Yesteryear: Where Are They Now?
We check back with previous Pharm Exec Brand of the Year winners to see how things are going.
Africa: The Lost Continent No More
Driven by a rising GDP and calmer political and financial waters over the past decade, Africa's nascent healthcare sector is poised for a fresh surge in growth.
What's Real in Deals
Recent deal making signals that the rehabilitation of big Pharma has entered a new phase aligned around a new strategic thesis, writes Pharm Exec Editor-in-Chief William Looney.
2014 Brand of the Year
Pharm Exec's Brand of the Year recipients for 2014 are multiple sclerosis treatment Copaxone and KORLYM for diseases driven by excess production of the metabolic hormone, cortisol. We profile the journey of both drugs.
Does Your Rigor Match Your Risk?
Digital technology has changed the risk relationship between brands, HCPs, and patients – it's vital to get that technology working right the first time.
